Bachem brings manufacturing perspectives to London Peptides Congress
News | Bachem AG
APRIL 08, 2019
Bubendorf, Switzerland: –‘Pioneering Partner for Peptides’ Bachem AG will be a prominent presence at the upcoming 6th Annual Peptides Congress in London.
Bachem will be a Bronze Sponsor of the event and an exhibitor from Booth 1 at the Novotel London West in Hammersmith, West London. Its display will showcase its ever-expanding portfolio of CMO capabilities in peptide-based active pharmaceutical ingredients (APIs) and innovative selective glycosylation processes.
Linear vs Convergent Peptide Synthesis
Bachem will also offer insights into production realities during the conference,. with its Team Leader for Research & Development, Dr. Alain Schlatter, presenting ‘Linear And Convergent Approaches To Peptide Synthesis – A Comparison From A Manufacturer’s Point Of View’ during the Peptides stream on Day One (0930-1000 hrs, April 24).
Bachem has been closely associated with the Peptides Congress almost since its inception in 2013 with regular attendance, sponsorship and active contribution to the conference streams.
Small molecule APIs
The Bachem stand will also focus on its innovative portfolio of small molecule APIs and proprietary processes that harness its outstanding knowledge of peptide and carbohydrate chemistry.
Over recent months, Bachem’s award-winning single glycosylation process enabled production scale chemical synthesis of Interferon β-1a, along with custom manufacturing, synthetic organic chemistry, generic peptidic and small molecule APIs.
The Bachem Group is the world’s only full service provider of peptides and provides a full range of other services to the pharma and biotech industries.
Under its banner Pioneering Partner for Peptides, Bachem specializes in the process development and manufacture of peptides and complex organic molecules as active pharmaceutical ingredients (APIs).
A comprehensive catalog of innovative biochemicals for research and exclusive custom syntheses for research labs complete its service portfolio.
Headquartered in Switzerland with subsidiaries in Europe, the US and Asia, the group has a global reach and shows total commitment to quality, innovation and partnership to its customers worldwide.
Bachem prioritizes continuous investment in R&D on chemistries and technologies as crucial for future success. Its ever-increasing knowledge of complex proteins and peptides derives from ongoing research in proteomics, as well as progress in mass spectrometry, synthesis and ligation technologies, complemented by collaboration with external research institutions.
Bachem has six production sites in the U.S. and in Europe along with research level production and full cGMP manufacturing facilities on both continents. These provide capacity to produce APIs, key intermediates, small molecule generics and new chemical entities (NCEs).
About Peptides Congress 2019
The Annual Peptides Congress combines three events in one, being co-located with the 12th Annual Proteins & Antibodies Congress and the 6th Annual Biosimilars & Biobetters Congress. Together they will attract more than 450 peptides, proteins and antibodies professionals representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions.
The conference will include some 25 presentations and case studies focusing on the key advancements in peptide development, therapeutics and formulation, delivery and manufacturing.
The joint congresses form a two-day event, opening April 24 at the Novotel London West in Hammersmith, West London. The conference sessions will address three main themes: Peptide Discovery, Chemistry and Analytical Technologies, Peptide Therapeutics and Peptide Delivery and Formulation.
The events are organized by Oxford Global with further information at: https://www.oxfordglobal.co.uk/peptides-congress/
Dr. Martina Diekmann, Vice-President, Global Marketing, Bachem Group
Tel: +41 799 459 107